BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 37372326)

  • 1. Potential Prognostic Value of GATA4 Depends on the p53 Expression in Primary Glioblastoma Patients.
    Trąbska-Kluch B; Braun M; Orzechowska M; Paszek S; Zuchowska A; Sołek J; Kluska A; Fijuth J; Jesionek-Kupnicka D; Zawlik I
    Genes (Basel); 2023 May; 14(6):. PubMed ID: 37372326
    [TBL] [Abstract][Full Text] [Related]  

  • 2. GATA4 and DcR1 methylation in glioblastomas.
    Vaitkienė P; Skiriutė D; Skauminas K; Tamašauskas A
    Diagn Pathol; 2013 Jan; 8():7. PubMed ID: 23320456
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A GATA4-regulated tumor suppressor network represses formation of malignant human astrocytomas.
    Agnihotri S; Wolf A; Munoz DM; Smith CJ; Gajadhar A; Restrepo A; Clarke ID; Fuller GN; Kesari S; Dirks PB; McGlade CJ; Stanford WL; Aldape K; Mischel PS; Hawkins C; Guha A
    J Exp Med; 2011 Apr; 208(4):689-702. PubMed ID: 21464220
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High incidence of MGMT promoter methylation in primary glioblastomas without correlation with TP53 gene mutations.
    Jesien-Lewandowicz E; Jesionek-Kupnicka D; Zawlik I; Szybka M; Kulczycka-Wojdala D; Rieske P; Sieruta M; Jaskolski D; Och W; Skowronski W; Sikorska B; Potemski P; Papierz W; Liberski PP; Kordek R
    Cancer Genet Cytogenet; 2009 Jan; 188(2):77-82. PubMed ID: 19100509
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of MGMT promoter methylation and TP53 mutation in glioblastomas depends on IDH1 mutation.
    Wang K; Wang YY; Ma J; Wang JF; Li SW; Jiang T; Dai JP
    Asian Pac J Cancer Prev; 2014; 15(24):10893-8. PubMed ID: 25605197
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TP53 promoter methylation in primary glioblastoma: relationship with TP53 mRNA and protein expression and mutation status.
    Jesionek-Kupnicka D; Szybka M; Malachowska B; Fendler W; Potemski P; Piaskowski S; Jaskolski D; Papierz W; Skowronski W; Och W; Kordek R; Zawlik I
    DNA Cell Biol; 2014 Apr; 33(4):217-26. PubMed ID: 24506545
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MGMT promoter hypermethylation is a frequent, early, and consistent event in astrocytoma progression, and not correlated with TP53 mutation.
    Groenendijk FH; Taal W; Dubbink HJ; Haarloo CR; Kouwenhoven MC; van den Bent MJ; Kros JM; Dinjens WN
    J Neurooncol; 2011 Feb; 101(3):405-17. PubMed ID: 20593220
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypermethylation of the GATA binding protein 4 (GATA4) promoter in Chinese pediatric acute myeloid leukemia.
    Tao YF; Fang F; Hu SY; Lu J; Cao L; Zhao WL; Xiao PF; Li ZH; Wang NN; Xu LX; Du XJ; Sun LC; Li YH; Li YP; Xu YY; Ni J; Wang J; Feng X; Pan J
    BMC Cancer; 2015 Oct; 15():756. PubMed ID: 26490736
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Importance of promoter methylation of GATA4 and TP53 genes in endometrioid carcinoma of endometrium.
    Chmelarova M; Kos S; Dvorakova E; Spacek J; Laco J; Ruszova E; Hrochova K; Palicka V
    Clin Chem Lab Med; 2014 Aug; 52(8):1229-34. PubMed ID: 24651021
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of TP53 expression and MGMT methylation in glioblastoma patients treated with temozolomide combined with other chemotherapies.
    Kurdi M; Butt NS; Baeesa S; Alghamdi B; Maghrabi Y; Bardeesi A; Saeedi R; Dallol A; Mohamed F; Bari MO; Samkari A; Lary AI; Alkhayyat S
    J Neurooncol; 2021 May; 152(3):541-549. PubMed ID: 33661424
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network.
    Weller M; Felsberg J; Hartmann C; Berger H; Steinbach JP; Schramm J; Westphal M; Schackert G; Simon M; Tonn JC; Heese O; Krex D; Nikkhah G; Pietsch T; Wiestler O; Reifenberger G; von Deimling A; Loeffler M
    J Clin Oncol; 2009 Dec; 27(34):5743-50. PubMed ID: 19805672
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic impact of TP53 mutation status for adult patients with supratentorial World Health Organization Grade II astrocytoma or oligoastrocytoma: a long-term analysis.
    Ständer M; Peraud A; Leroch B; Kreth FW
    Cancer; 2004 Sep; 101(5):1028-35. PubMed ID: 15329912
    [TBL] [Abstract][Full Text] [Related]  

  • 13. O6-methylguanine-DNA methyltransferase methylation and TP53 mutation in malignant astrocytomas and their relationships with clinical course.
    Watanabe T; Katayama Y; Komine C; Yoshino A; Ogino A; Ohta T; Fukushima T
    Int J Cancer; 2005 Feb; 113(4):581-7. PubMed ID: 15455376
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic impact of TP53 mutations and P53 protein overexpression in supratentorial WHO grade II astrocytomas and oligoastrocytomas.
    Peraud A; Kreth FW; Wiestler OD; Kleihues P; Reulen HJ
    Clin Cancer Res; 2002 May; 8(5):1117-24. PubMed ID: 12006527
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deregulation of the TP53/p14ARF tumor suppressor pathway in low-grade diffuse astrocytomas and its influence on clinical course.
    Watanabe T; Katayama Y; Yoshino A; Komine C; Yokoyama T
    Clin Cancer Res; 2003 Oct; 9(13):4884-90. PubMed ID: 14581362
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic significance of MGMT methylation and expression of MGMT, P53, EGFR, MDM2 and PTEN in glioblastoma multiforme.
    Limam S; Missaoui N; Abdessayed N; Mestiri S; Selmi B; Mokni M; Yacoubi MT
    Ann Biol Clin (Paris); 2019 Jun; 77(3):307-317. PubMed ID: 31131831
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic significance of histological grading, p53 status, YKL-40 expression, and IDH1 mutations in pediatric high-grade gliomas.
    Antonelli M; Buttarelli FR; Arcella A; Nobusawa S; Donofrio V; Oghaki H; Giangaspero F
    J Neurooncol; 2010 Sep; 99(2):209-15. PubMed ID: 20174854
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IDH1 mutations in grade II astrocytomas are associated with unfavorable progression-free survival and prolonged postrecurrence survival.
    Thon N; Eigenbrod S; Kreth S; Lutz J; Tonn JC; Kretzschmar H; Peraud A; Kreth FW
    Cancer; 2012 Jan; 118(2):452-60. PubMed ID: 21717448
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LINE-1 hypomethylation is associated with poor outcomes in locoregionally advanced oropharyngeal cancer.
    Casarotto M; Lupato V; Giurato G; Guerrieri R; Sulfaro S; Salvati A; D'Angelo E; Furlan C; Menegaldo A; Baboci L; Montico B; Turturici I; Dolcetti R; Romeo S; Baggio V; Corrado S; Businello G; Guido M; Weisz A; Giacomarra V; Franchin G; Steffan A; Sigalotti L; Vaccher E; Boscolo-Rizzo P; Jerry P; Fanetti G; Fratta E
    Clin Epigenetics; 2022 Dec; 14(1):171. PubMed ID: 36503584
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aberrantly hypermethylated tumor suppressor genes were identified in oral squamous cell carcinoma (OSCC).
    Kim SY; Han YK; Song JM; Lee CH; Kang K; Yi JM; Park HR
    Clin Epigenetics; 2019 Aug; 11(1):116. PubMed ID: 31405379
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.